Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase Ib trial of inhaled iloprost for the prevention of lung cancer with predictive and response biomarker assessment.
Miller YE, Ghosh M, Merrick DT, Kubala B, Szabo E, Bengtson L, Kocherginsky M, Helenowski IB, Benante K, Schering T, Kim J, Kim H, Ha D, Bergan RC, Khan SA, Keith RL. Miller YE, et al. Among authors: bergan rc. Front Oncol. 2023 Aug 30;13:1204726. doi: 10.3389/fonc.2023.1204726. eCollection 2023. Front Oncol. 2023. PMID: 37711198 Free PMC article.
FDA Approval Summary: Belzutifan for VHL Disease Tumors-Letter.
Trinh JQ, Ellithi M, Shonka N, Bergan RC. Trinh JQ, et al. Among authors: bergan rc. Clin Cancer Res. 2023 Feb 1;29(3):684. doi: 10.1158/1078-0432.CCR-22-2968. Clin Cancer Res. 2023. PMID: 36722140 Free PMC article. No abstract available.
Characterizing advanced breast cancer heterogeneity and treatment resistance through serial biopsies and comprehensive analytics.
Li A, Keck JM, Parmar S, Patterson J, Labrie M, Creason AL, Johnson BE, Downey M, Thomas G, Beadling C, Heiser LM, Kolodzie A, Guimaraes AR, Corless CL, Gray JW, Mills GB, Bergan RC, Mitri ZI. Li A, et al. Among authors: bergan rc. NPJ Precis Oncol. 2021 Mar 26;5(1):28. doi: 10.1038/s41698-021-00165-4. NPJ Precis Oncol. 2021. PMID: 33772089 Free PMC article.
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Graff JN, Beer TM, Alumkal JJ, Slottke RE, Redmond WL, Thomas GV, Thompson RF, Wood MA, Koguchi Y, Chen Y, Latour E, Bergan RC, Drake CG, Moran AE. Graff JN, et al. Among authors: bergan rc. J Immunother Cancer. 2020 Jul;8(2):e000642. doi: 10.1136/jitc-2020-000642. J Immunother Cancer. 2020. PMID: 32616555 Free PMC article. Clinical Trial.
Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.
Graff JN, Alumkal JJ, Drake CG, Thomas GV, Redmond WL, Farhad M, Cetnar JP, Ey FS, Bergan RC, Slottke R, Beer TM. Graff JN, et al. Among authors: bergan rc. Oncotarget. 2016 Aug 16;7(33):52810-52817. doi: 10.18632/oncotarget.10547. Oncotarget. 2016. PMID: 27429197 Free PMC article. Clinical Trial.
68 results